Insider Transactions in Q3 2025 at Recursion Pharmaceuticals, Inc. (RXRX)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 26
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-9.49%
|
$400,000
$4.84 P/Share
|
|
Aug 26
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100,000
+8.66%
|
-
|
|
Aug 18
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Open market or private sale
|
Direct |
36,599
-5.19%
|
$182,995
$5.52 P/Share
|
|
Aug 15
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,789
-0.53%
|
$18,945
$5.64 P/Share
|
|
Aug 15
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
40,390
-4.06%
|
$201,950
$5.64 P/Share
|
|
Aug 15
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,908
-1.45%
|
$59,540
$5.64 P/Share
|
|
Aug 11
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
117,875
-100.0%
|
$589,375
$5.28 P/Share
|
|
Aug 11
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
117,875
+50.0%
|
-
|
|
Aug 11
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
10,000
-1.0%
|
-
|
|
Aug 11
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
500,300
-33.24%
|
$2,501,500
$5.28 P/Share
|
|
Aug 11
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
423,666
+21.97%
|
-
|
|
Jul 01
2025
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,924
+2.11%
|
-
|
|
Jul 01
2025
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,949
+0.16%
|
-
|